Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin
Stream: Advanced Therapies
Kenneth Moch is a skilled advisor, CEO, Board leader and strategist with proven experience building and financing private and public life science companies from start-up through commercialization, from VC financings to multiple IPOs. A team builder and leader with strong industry relationships and demonstrated ability to manage complex situations, he has played a key role in building six life science companies, resulting in multiple marketed products focused on the treatment of chronic and acute life-threatening conditions.
At the essence, there are three aspects to Ken’s endeavors: company building (both as a CEO and as an advisor); public policy (through his leadership positions with both state and national biotech policy organizations); and patient advocacy/bioethics (arising from his experience with compassionate use/expanded access issues while CEO of Chimerix). Ken is currently serving as a Senior Advisor to the Chairman of the Center for Global Health Innovation and the Global Health Crisis Coordination Center. He previously served as President & CEO of five life science companies – Cognition Therapeutics, Chimerix, BioMedical Enterprises, Alteon and Biocyte Corporation – having started his career in biotech drug development as a co-founder of The Liposome Company, the pioneering company for lipid nanoparticles, one of the most widely used drug delivery/carrier technologies. His work with Cognition, Chimerix and Liposome led to IPOs. He has also been a Managing Director of Healthcare Investment Banking at ThinkEquity Partners and a management consultant with McKinsey & Company.
Ken served for over a decade on the Governing Board of the Biotechnology Innovation Organization (BIO), most recently chairing BIO’s Bioethics Committee and co-chairing the Emerging Companies Section Strategy and Policy Committee, and is a past Chairman of BioNJ, New Jersey’s biotechnology trade organization. He is a founding member of the New York University Working Group on Compassionate Use and Pre-Approval Access and a Faculty Affiliate of the Division of Medical Ethics, Department of Population Health, NYU School of Medicine. His experiences relating to strategic and ethical issues in pre-approval access to experimental medicines are the subject of a 2021 Harvard Business School Case Study, “Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix.”
Ken received an A.B. in biochemistry with a minor in health policy from Princeton University and an MBA from the Stanford University Graduate School of Business.